Key facts
- This page summarizes Markus Warmuth's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2025, 16:15.
Markus Warmuth - 02 Jan 2025 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- GLUE
- Reported as of
- 02 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2025, 16:15:09 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 05 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Markus Warmuth
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Markus Warmuth filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 06 Jan 2025.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GLUE
transaction
Common Stock
Award
- Transaction value
- Shares
- +128,000
- Change %
- +31%
- Price
- Shares after
- 544,538
- Date
- 02 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GLUE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +575,000
- Change %
- Price
- $0.000000
- Shares after
- 575,000
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 575,000
- Exercise price
- $7.11
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.